Product Description: Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021./[2]Masugi Y, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 Aug;66(8):1463-1473.
CAS Number: 2475402-56-1
Molecular Weight: N/A
Compound Purity: 97.34
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others